The advent of immune checkpoint inhibitors (ICIs) has transformed the treatment landscape of various malignancies. While these therapies have demonstrated significant efficacy, they are often accompanied by immune-related adverse events (irAEs). Among these, hematologic immune-related toxicities are notably rare. Here, we describe 2 cases of immunotherapy-associated autoimmune hemolytic anemia (ir-AIHA) following the use of programmed cell death 1 (PD-1) ICIs in patients with locally advanced melanoma and cervical cancer. With the increasing use of ICIs, it is essential for physicians to maintain a high index of clinical suspicion for this rare but serious irAE, ensuring timely diagnosis and effective management to optimize patient outcomes.
Gouveia et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: